These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17251913)

  • 1. Dopamine and serotonin receptor binding and antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Neuropsychopharmacology; 2007 Aug; 32(8):1715-26. PubMed ID: 17251913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of serotonin and dopamine receptor binding in antipsychotic efficacy.
    Richtand NM; Welge JA; Logue AD; Keck PE; Strakowski SM; McNamara RK
    Prog Brain Res; 2008; 172():155-75. PubMed ID: 18772032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Kroeze WK; Hufeisen SJ; Popadak BA; Renock SM; Steinberg S; Ernsberger P; Jayathilake K; Meltzer HY; Roth BL
    Neuropsychopharmacology; 2003 Mar; 28(3):519-26. PubMed ID: 12629531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
    Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.
    Ueda T; Ugawa S; Ishida Y; Shimada S
    Eur J Pharmacol; 2011 Dec; 671(1-3):79-86. PubMed ID: 21951966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes.
    Oberweis B; Gragnoli C
    J Cell Physiol; 2012 Aug; 227(8):3001-6. PubMed ID: 22105468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K; Grinde E; Teitler M
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-cinnamyl-4-(2-methoxyphenyl)piperazines: synthesis, binding properties, and docking to dopamine (D(2)) and serotonin (5-HT(1A)) receptors.
    Penjisević J; Sukalović V; Andrić D; Kostić-Rajacić S; Soskić V; Roglić G
    Arch Pharm (Weinheim); 2007 Sep; 340(9):456-65. PubMed ID: 17763374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a series of aminoalkyl-tetralones and tetralols as dual dopamine/serotonin ligands.
    Carro L; Torrado M; Raviña E; Masaguer CF; Lage S; Brea J; Loza MI
    Eur J Med Chem; 2014 Jan; 71():237-49. PubMed ID: 24316025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
    Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.